Autopsy report · NCT03202147

Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study halted prematurely prior to initiation but potentially will resume in the future.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: AZTherapies, Inc.
Sponsor type: Industry
Conditions: Ischemic Stroke; Post-stroke Cognitive Impairment
Interventions: Cromolyn; Placebo
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.